Physiomics PLC (GB:PYC)
LSE:PYC
Want to see GB:PYC full AI Analyst Report?
Top Page
Physiomics
(LSE:PYC)
Select Model
Select Model
Rating:53Neutral
Price Target:
0.66 p
▲(135.71% Upside)
Action:Reiterated
Date:05/22/26
The score is held back mainly by weak financial performance—continued net losses and recurring negative operating/free cash flow—despite a cleaner, low-debt balance sheet. Technicals provide support with the price above major moving averages and positive MACD, while valuation is mixed due to a negative P/E and no indicated dividend yield.
Positive Factors
Low leverage / clean balance sheet
Zero reported debt and a modest equity cushion reduce refinancing and interest-rate risk, giving the firm flexibility to fund operations or strategic investments from equity or cash reserves. This structural low-leverage profile improves resilience while cash burn is addressed over months.
Negative Factors
Recurring negative operating and free cash flow
Sustained negative operating and free cash flow requires external financing or equity issuance to sustain operations, constraining strategic choices. Over a multi-quarter horizon this elevates dilution and refinancing risk, regardless of top-line improvements, until cash generation turns positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / clean balance sheet
Zero reported debt and a modest equity cushion reduce refinancing and interest-rate risk, giving the firm flexibility to fund operations or strategic investments from equity or cash reserves. This structural low-leverage profile improves resilience while cash burn is addressed over months.
Read all positive factors
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.49M
Dividend YieldN/A
Average Volume (3M)2.43M
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth91.27%
EPS Growth60.98%
CountryUK
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume1,168,038
30 Day Avg. Volume2,434,740
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Physiomics Business Overview & Revenue Model
Company Description
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation...
How the Company Makes Money
Physiomics primarily makes money by selling modelling and simulation work to external customers on a contract basis. The core revenue stream is fee-for-service project income, where clients (typically pharmaceutical and biotechnology companies and...
Physiomics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 953.00K | 784.00K | 543.25K | 597.35K | 830.27K | 702.31K |
| Gross Profit | -543.08K | -435.08K | -677.43K | -581.62K | -429.01K | -365.79K |
| EBITDA | -553.33K | -448.21K | -659.80K | -561.57K | -347.84K | -324.52K |
| Net Income | -485.25K | -415.25K | -609.35K | -477.26K | -253.14K | -215.83K |
Balance Sheet | ||||||
| Total Assets | 558.00K | 892.03K | 422.60K | 674.39K | 1.12M | 1.32M |
| Cash, Cash Equivalents and Short-Term Investments | 257.00K | 461.24K | 191.07K | 416.59K | 687.67K | 1.04M |
| Total Debt | 0.00 | 0.00 | 3.83K | 7.35K | 0.00 | 0.00 |
| Total Liabilities | 165.00K | 199.85K | 140.08K | 142.67K | 140.61K | 157.57K |
| Stockholders Equity | 393.00K | 692.17K | 282.53K | 531.72K | 974.81K | 1.17M |
Cash Flow | ||||||
| Free Cash Flow | -469.08K | -550.08K | -565.44K | -271.50K | -358.62K | -48.65K |
| Operating Cash Flow | -464.14K | -546.14K | -548.13K | -264.86K | -349.25K | -32.50K |
| Investing Cash Flow | -4.41K | -3.41K | -15.21K | -6.22K | -9.37K | -16.15K |
| Financing Cash Flow | 456.73K | 819.73K | 337.83K | 0.00 | 2.85K | 44.24K |
Physiomics Technical Analysis
Positive
0.28
Price Trends
0.49
Positive
0.45
Positive
0.43
Positive
Market Momentum
0.02
Positive
54.36
Neutral
39.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PYC, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.49, and below the 200-day MA of 0.43, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 54.36 is Neutral, neither overbought nor oversold. The STOCH value of 39.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PYC.
Physiomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £2.49M | -0.72 | -89.43% | ― | 91.27% | 60.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £18.53M | -4.43 | -15.57% | ― | 13.04% | 15.88% | |
50 Neutral | £4.94M | -0.88 | -53.79% | ― | ― | 85.56% | |
43 Neutral | £5.94M | -2.61 | -2.42% | ― | 102.28% | 95.58% | |
41 Neutral | £1.41M | -0.64 | ― | ― | 418.49% | 45.35% | |
40 Underperform | £8.15M | -0.25 | -316.67% | ― | 72.17% | 79.03% |
* Healthcare Sector Average
GB:PYC
Physiomics
0.65
0.23
54.76%
GB:TCF
Evgen Pharma
0.23
>-0.01
-4.17%
GB:IXI
IXICO plc
8.65
-2.85
-24.78%
GB:OPTI
OptiBiotix Health
5.75
-12.50
-68.49%
GB:OBD
Oxford BioDynamics
0.19
-0.13
-40.63%
GB:VAL
ValiRx plc
0.20
-0.36
-64.55%
Physiomics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Physiomics Extends CEO Peter Sargent’s Tenure Amid Strategic Transition
Positive
May 15, 2026
Physiomics plc has announced that CEO Peter Sargent has agreed to extend his current agreement and will remain in his role through June 2026, providing continuity as the company navigates a period of significant internal change. The board is in on...
Business Operations and StrategyExecutive/Board Changes
Physiomics appoints transformation specialist to steer leadership transition and growth strategy
Positive
May 12, 2026
Physiomics plc, a UK-based specialist in mathematical modelling, data science and biostatistics for drug development and personalised medicine, provides computational tools and bespoke models to help biotech and pharma companies de-risk decisions ...
Business Operations and StrategyExecutive/Board Changes
Physiomics’ New Board Launches Strategic Overhaul to Drive Growth and Discipline
Positive
May 8, 2026
Physiomics’ newly appointed board has launched a wide-ranging strategic review aimed at sharpening operational efficiency, strengthening commercial execution and driving long-term shareholder value. The company highlights underappreciated st...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics shareholders back investor-led board overhaul at AIM-listed modelling firm
Neutral
Apr 29, 2026
Physiomics plc has undergone a significant boardroom shake-up after shareholders at a requisitioned general meeting backed all resolutions, installing three new directors and removing four incumbent board members. Entrepreneur and major shareholde...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics shareholders back board overhaul as new investor-led team takes control
Neutral
Apr 29, 2026
Physiomics plc, a mathematical modelling and data science company serving the biopharmaceutical sector, uses bespoke models and bioinformatics to de-risk drug development decisions and optimise study design across the RD lifecycle. Its Virtual Tum...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics Urges Shareholders to Reject Activist Bid to Replace Board
Negative
Apr 24, 2026
Physiomics has urged shareholders to vote against all resolutions tabled for a requisitioned general meeting on 29 April, which seek to remove the entire existing board and replace it with nominees of activist investor Mike Whitlow. The company ar...
Business Operations and StrategyShareholder Meetings
Physiomics Launches Shareholder Website Ahead of Requisitioned General Meeting
Neutral
Apr 22, 2026
Physiomics plc, a leading AIM‑quoted modelling and data science company serving biotech and pharma clients in oncology and other therapeutic areas, uses bespoke computational models and biostatistics to inform drug development. Its Virtual T...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
ISS backs Physiomics board in proxy fight over requisitioned meeting
Neutral
Apr 17, 2026
Institutional Shareholder Services has advised investors in Physiomics to vote against resolutions at a 29 April requisitioned general meeting that seek to remove the existing board and install new directors, citing the lack of a detailed or credi...
Business Operations and Strategy
Physiomics Wins New Oncology Modelling Contract from Numab Therapeutics
Positive
Apr 14, 2026
Physiomics plc, a mathematical modelling and data science consultancy serving the biopharmaceutical sector, has secured a new contract with long-standing client Numab Therapeutics AG. The engagement centres on applying model-informed drug developm...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics Urges Shareholders to Reject Activist Board Shake-Up
Negative
Apr 8, 2026
Physiomics has urged shareholders to vote against resolutions proposed for a requisitioned general meeting on 29 April 2026, arguing that the activist-led bid to reshape the board is premature and could disrupt the company’s commercialisatio...
Executive/Board ChangesShareholder Meetings
Physiomics Board Urges Shareholders to Reject Investor-Led Board Overhaul
Negative
Apr 2, 2026
Physiomics has published a circular convening a requisitioned general meeting on 29 April 2026 after shareholder Michael Whitlow, who holds about 12.35% of the company, sought to overhaul the board by appointing three new directors and removing fo...
Private Placements and FinancingShareholder Meetings
Physiomics cancels general meeting after improving terms of equity placing
Positive
Mar 20, 2026
Physiomics has cancelled the general meeting that had been scheduled for 7 April 2026 after revising the terms of its previously announced equity fundraising. The board scrapped the original placing at 0.3 pence per share and instead completed, su...
Business Operations and StrategyPrivate Placements and Financing
Physiomics Raises £600,000 Via Retail Offer and Placing to Support Growth
Positive
Mar 18, 2026
Physiomics plc, a UK AIM-listed specialist in modelling, simulation and data-driven decision support for drug development and personalised medicine, provides computational tools and bespoke models that help streamline discovery, pre-clinical and c...
Business Operations and StrategyPrivate Placements and Financing
Physiomics launches revised WRAP retail offer alongside £490,000 placing
Neutral
Mar 17, 2026
Physiomics plc has launched a revised retail equity offer via Winterflood’s Retail Access Platform to raise up to £110,000 by issuing as many as 27.5 million new shares at £0.004, matching the price of a concurrent £490,000 in...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Physiomics Raises £490,000 in Revised Placing and Launches Retail Offer to Fund Growth
Positive
Mar 17, 2026
Physiomics has raised £490,000 through a discounted placing of 122.5 million new shares at £0.004 each and plans to launch a WRAP retail offer of up to a further £110,000 for existing shareholders on the same terms. The revised fund...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics Faces Shareholder Push for Full Board Overhaul
Negative
Mar 16, 2026
Physiomics plc has received a shareholder requisition to convene a general meeting seeking to overhaul its board, led by investor Michael Whitlow, who holds about 13.68% of the company’s share capital. The proposed resolutions would appoint ...
Private Placements and FinancingShareholder Meetings
Physiomics Raises £673k in Oversubscribed Retail and Placing Fundraise
Positive
Mar 13, 2026
Physiomics plc has completed an oversubscribed WRAP Retail Offer, raising gross proceeds of £223,279.48 through the issue of 74,426,493 new ordinary shares at the same price as a previously announced placing. Together, the retail offer and pl...
Private Placements and FinancingShareholder Meetings
Physiomics Opens Retail Share Offer Alongside Discounted Placing
Neutral
Mar 10, 2026
Physiomics plc has launched a Winterflood Retail Access Platform offer to raise up to £49,999.98 by issuing up to 16,666,660 new ordinary shares at £0.003 each, matching the price of a concurrent institutional placing of approximately &#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.